Sophia Antipolis, France

Press Release – For immediate Release – 5:45 pm CET

Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/29/2023:

  • €106,617.89 in cash

During the second half of 2023, it has been traded a total of:

BUY96,229 SharesEUR 457,244.45338 transactions
SELL96,971 SharesEUR 461,187.31273 transactions

At the time of the half-yearly statement of 06/30/2023, the following resources were included in the liquidity account:

  • €105,784.53 in cash

When the new liquidity contract was put in place on 05/04/2020, the following resources were made available:

  • € 173,829.64 in cash

The daily transaction table is provided in the pdf version of the press release.

TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

Download 20240110_PR_LiquiditycontractH22023_EN.pdf

About Median Technologies

Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit


Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24